CRISPR Therapeutics AGCRSPNASDAQ
LOADING
|||
Cash Flow Under Pressure
Trending higher, below historical average.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-144.68M
↓ 66% below average
Average (9y)
$-87.39M
Historical baseline
Range
High:$457.27M
Low:$-532.93M
CAGR
NaN%
Modest growth trend
| Period | Value | Change |
|---|---|---|
| 2024 | $-144.68M | +46.4% |
| 2023 | $-269.85M | +49.4% |
| 2022 | $-532.93M | -216.5% |
| 2021 | $457.27M | +278.1% |
| 2020 | $-256.72M | -613.5% |
| 2019 | $49.99M | +150.5% |
| 2018 | $-99.01M | -27.1% |
| 2017 | $-77.91M | -33.6% |
| 2016 | $-58.33M | -200.1% |
| 2015 | $58.27M | - |